Pfizer asks FDA to clear updated COVID shot for kids under 5


Deborah Sampson, left, a nurse at a University of Washington Medical Center clinic in Seattle, gives a Pfizer COVID-19 vaccine shot to a 20-month-old child, June 21, 2022, in Seattle. Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5. The youngest tots already are supposed to get three extra-small doses of the original vaccine as their primary series. Pfizer and its partner BioNTech said Monday, Dec. 5, 2022 that if the Food and Drug Administration agrees, the updated vaccine would be used for the third shot. The FDA already has cleared COVID-19 vaccines tweaked to better target omicron as boosters for everyone 5 and older. (AP Photo/Ted S. Warren, file)

Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5 — not as a booster but part of their initial shots.

Children ages 6 months through 4 years already are supposed to get three extra-small doses of the original Pfizer COVID-19 vaccine — each a tenth of the amount adults receive — as their primary series. If the Food and Drug Administration agrees, a dose of Pfizer's bivalent omicron-targeting vaccine would be substituted for their third shot.

Pfizer and its partner BioNTech said Monday that may help prevent severe illness and hospitalization from COVID-19 in little kids, at a time when children’s hospitals already are packed with youngsters hit by other respiratory illnesses.

Few of the nation's youngest children have gotten their COVID-19 vaccinations since the shots were OK'd in June: Just 2% of tots under 2 and about 4% of 2- to 4-year-olds have gotten their primary doses so far, according to the Centers for Disease Control and Prevention.

The FDA has authorized the new bivalent COVID-19 shots — versions made by Pfizer and rival Moderna — as a booster for everyone ages 5 and older. Those combination shots contain half the original vaccine and half tweaked to match the BA.4 and BA.5 omicron strains that until recently were dominant. Now BA.5 descendants are responsible for most COVID-19 cases.

The CDC last month released the first real-world data showing that an updated booster, using either company's version, does offer added protection to adults. The analysis found the greatest benefit was in people who’d never had a prior booster, just two doses of the original COVID-19 vaccine -- but that even those who’d had a summertime dose were more protected than if they’d skipped the newest shot.

—-

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9743 of 5 stars
$25.40+0.6%6.61%70.56Hold$36.33
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

7 Stocks to Help You Build Off January’s Gains

7 Stocks to Help You Build Off January’s Gains

It's frequently said that as January goes, so goes the market. If that's the case, it's time for investors to put money to work in the stock market.

Search Headlines: